General information for participants
Arrival and registration
Arrival and registration
Registration and room allocation will take place at 16:00 in Undeloh (in front of the “Undeloher Hof”), where you also have the opportunity to park your car. After registration you should make your way to Wilsede, where you will be welcomed at the conference location. You will have time to meet the other participants and collect your name tags.
Information for presenters
Information for presenters
Presentations are 10 + 2 min (🏆) unless they are indicated as a short talk (🎯). Short talks are 7 + 2 min long. The exceptions will be our key note speakers for the invited lectures, who will be given 30 min time. Due to the large number of participants this year, we kindly ask you to stay within the time limit. We recommend to use a 16:9 formate for your presentation slides. Please also refer to the information you received via E-mail regarding the upload of your presentation. We have microsoft and IOS devices available for you to use to check and display your presentation from. Our friendly technical support will be located in the back of the conference room and available to assist you.
During your stay
During your stay
We advise you check the weather forecast, before you travel to Wilsede. The weather in July is usually fairly sunny and warm, so we recommend sun screen. However it might cool down in the evening and past events have also been accompanied by rain. We also note, that the roads/paths between Underloh and Wilsede are not paved and you may consider this when choosing footwear.
Shuttle service and horse carriage
At the day of arrival a shuttle service will be provided between 14:30-18:30 that will be departing from Handeloh train station to the registration in Undeloh. At the same day the first horse carriage rides will await you to take you from Undeloh to our conference location in Wilsede (last departure 16:45). From Thursday to Saturday horse carriages will also be available in the mornings (8:00) and evenings (23:00). The horse carriages will have two stops in Undeloh „Emhoff“ and „Undeloher Hof“, and one stop in Wilsede at the conference centre. At the end of the conference horse carriages will bring the guests a last time from Wilsede to Undeloh, from where shuttle services will be available from 11:30-14:30 to allow transfer between Undeloh and Handeloh Bahnhof.
WEDNESDAY, June 4, 2025
16:00 – 17:30
16:00 – 17:30
Arrival and registration
Registration
17:30 – 17:45
17:30-18:00
Opening speech
Welcome speech
by Rolf Marschalek & Jan-Henning Klusmann
17:45 – 19:00
18:00 – 19:00
(A) Appetizers
(A) Appetizers
Chair: Rolf Marschalek
A1. Riboflavin metabolism as a selective therapeutic vulnerability in Acute Myeloid Leukemia (AML) 
Fauth R; Boston
A2. Mechanism and vulnerabilities of the SAGA complex in leukemia
Beneder H; Vienna
A3. Exploring the local tumor infiltration of medulloblastoma into the adjacent brain tissue
Tonn S; Hamburg
A4. Preemptive targeting of preleukemic cells with pathway-directed therapies: a novel approach to prevent myeloid leukemia
Schmell AL; Frankfurt am Main
A5. Spatial transcriptomics in paediatric and adult acute myeloid leukaemia: unravelling the bone marrow microenvironment
van der Meulen M; Utrecht
19:00 – 19:30
19:00 – 19:30
(B) Invited Lecture I
(B) Invited lecture I
Chair: Jan-Henning Klusmann
Ulrich Steidl, M.D., Ph.d.
Transcription Dynamics in Normal and Malignant Stem Cells
Professor and Chair of the Department for Cell Biology, Albert Einstein College of Medicine, New York, USA
19:30
19:30
Dinner
Dinner
THURSDAY, June 5, 2025
09:00 – 10:30
09:00 – 10:30
(C) Translation and therapy I
(C) Translation & Therapy
Chair: Marit Vermunt
C1. Towards new therapeutic strategies in t(4;11) leukemia
Dietz A; Frankfurt am Main
C2. Elucidating the role of Exportin-1 (XPO1) in NPM1c-driven acute myeloid leukemogenesis
González Dammers H; Frankfurt am Main
C3. TMZ Sensitization in GBM Cell Lines by Sequential Fadraciclib Treatment: An MGMT-Independent Strategy
Faerber J; Rostock
C4. Relapse Mechanisms in Children with Down Syndrome and Myeloid Leukemia
Rohde K; Frankfurt
C5. Development of an Imaging-Based High-Throughput Platform for Ex Vivo Agent Treatment in Patient-Derived AML Cells
van dem Bedem S; Utrecht
C6. Patient-Derived Xenograft Models in Leukemia Research: Advancing Preclinical Studies
Wei X; Frankfurt am Main
C7. Therapy-induced senescence shapes tumor biology and treatment outcome in hepatoblastoma 
Fankhänel L; Berlin
C8. Investigating Senescence-Induced Tumor Plasticity in High Risk Neuroblastoma
Seyboldt H; Berlin
10:30 – 11:00
10:30 – 11:00
Coffee break
Coffee break
11:00 – 12:30
11:00 – 12:30
(D) Signal transduction
(D) Malignant Cell Biology
Chair: Florian Grebien
D1. Deciphering the interplay between DNA methylation and CTCF in AML
Zhang Z; Frankfurt am Main
D2. Unveiling the Molecular Complexity of AML through Advanced Multi-Omics Analysis
Schuschel K; Frankfurt am Main
D3. A FRET-based approach to identify critical factors for biomolecular condensation in NUP98::KDM5A-driven AML
Kaufmann G; Vienna
D4. SNHG29 is a novel megakaryoblastic leukemia specific lncRNA dependency
Winkler R; Frankfurt am Main
D5. Deciphering the role of KANSL1 mutations in the development of Myeloid Leukemia in children with Down Syndrome (ML-DS)
Cases i Palau S; Frankfurt am Main
D6. Epigenetic remodeling via HDAC6 inhibition amplifies T cell responses in pediatric myeloid lineage leukemia
Tu JW; Düsseldorf
D7. A quiescence/TGF-β1 CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML
Rahimian E; Dresden
D8. Understanding the role of linear ubiquitination in lysophagy and lysosome-mediated cell death in acute myeloid leukemia
Schultze-Seemann F; Frankfurt am Main
12:30 – 14:00
12:30 – 14:00
Lunch (Wilsede, Heidemuseum)
Lunch (Wilsede, Heidemuseum)
14:00 – 14:30
14:00 – 14:30
(E) Invited Lecture II
(E) Invited Lecture II
Chair: Olaf Heidenreich
Prof. Dr. rer. nat. Katharina Imkeller
Decoding Adaptive Immune Response within the Tumor Microenviroment
Professor for Translational Neurooncology and Quantitative Immunology, Goethe University Frankfurt, Germany
14:30 – 15:30
(F) Tumor Microenvironment
14:30 – 15:30
(F) Tumor Microenviroment
Chair: Roland Kappler
F1. Beneficial impact of bone marrow supportive tissues on acute lymphoblastic leukemia
van de Ven C; Utrecht
F2. Molecular and histological analyses of AT/RT-TYR suggest the choroid plexus of the fourth ventricle as cellular origin
Altendorf L; Hamburg
F3. Inter- and intratumoral heterogeneity in MYCN-amplified spinal ependymoma
Ghasemi D R; Hamburg
F4. Deciphering impact of B-cell precursor acute lymphoblastic leukemia bone marrow microenvironment on immune cell function
Schreuders E; Utrecht
F5. Targeting senescence as anti-lymphoma strategy
Langer C; Frankfurt am Main
15:30 – 16:00
15:30 – 16:00
Coffee break
Coffee break
16:00 – 17:30
16:00 – 17:30
(G) Molecular mechanisms of disease I
(G) Molecular Mechanisms of Disease I
Chair: Davide Seruggia
G1. Analysis of novel transcripts and alternative isoform usage in acute myeloid leukemia
Zhong T; Frankfurt am Main
G2. RACK1 as a novel therapeutic target against Acute Myeloid Leukemia stem cells
Meseguer-Girón A; Badalona
G3. Analyzing Transcriptomic Alternative Landscapes in Pediatric AML: Insights from Long-Read RNA Sequencing
Gonçalves-Dias J; Frankfurt am Main
G4. Functional identification and targeting of zinc-finger containing proteins at domain resolution in leukemia
Horstmann C S; Vienna
G5. Targeting novel chromatin vulnerabilities in childhood acute myeloid leukemia
Schüler L; Frankfurt am Main
G6. Investigating the cooperating factors of NPM1c on chromatin in AML
Barros da Gama S; Frankfurt am Main
G7. The induction of CRISPR/Cas9-mediated KMT2A-rearrangements in umbilical cord blood HSPCs in vitro
Benz T; Frankfurt am Main
18:00 – 18:30
(H) Invited Lecture III
18:30 – 19:00
(H) Invited lecture III
Chair: Martin Stanulla
Ulrich Schüller
News & Views on the classification of medulloblastoma
Professor for Developmental Neurobiology and Pediatric Neurooncology, Universitätsklinikum Hamburg-Eppendorf , Hamburg, Germany
19:00
19:00
Dinner
Barbecue
FRIDAY, June 6, 2025
09:00 – 10:30
09:00 – 10:30
(I) Immunotherapy
(I) Immunotherapy I
Chair: Lennart Lenk
I1. Production of Universal CAR-T cells against the αβ-TCR with All-in-one Nanoblades
Wentzky L; Hamburg
I2. Memory-like NK cell and CD19-antibody based immunotherapy combined with TKI has antitumor effects against Ph(-like) ALL
Lane A; Hamburg
I3. CD127-directed immunotherapy outperforms Imatinib in preclinical ABL-class fusion+ BCP-ALL via a dual mode of action
Pinkle D; Kiel
I4. Comparison of VHH- and scFv-based CLEC12A-chimeric antigen receptor-natural killer cells against acute myleoid leukemia
Gierschek F; Frankfurt am Main
I5. Mesenchymal Stromal Cells do not suppress CAR-T function in B-Cell Precursor Acute Lymphoblastic Leukemia🏆
Debou C M A; Utrecht
I6. Multi-functional potency assay for CAR-NK cells: Mapping cytotoxicity, degranulation and proliferation in one
Schlueter J; Frankfurt am Main
I7. CRISPR-based optimization of CAR NK cell therapy for pediatric AML
Mair L; Frankfurt am Main
I8. Optimizing Antibody Production for Neuroblastoma Using a Hollow-Fiber Bioreactor
Landwehr M; Hamburg
10:30 – 11:00
10:30 – 11:00
Coffee break
Coffee break
11:00 – 12:30
11:00 – 12:30
(J) Biomarkers
(J) Biomarkers
Chair: Monique den Boer
J1. Rapid Epigenomic Classification of Acute Leukemia
Steinicke TL; Boston
J2. Enhancing Nanopore cfDNA diagnostics of pediatric brain tumors with machine learning
Appelt A; Hamburg
J3. ctDNA from preoperatively collected CSF predicts molecular classification of brain tumors
Freese J; Hamburg
J4. Minimal Invasive Detection of Circulating Biomarkers in Pediatric Cancer Patients Undergoing Chimeric Antigen Recepto
Wahlbrink E H; Heidelberg
J5. CCND3 Knockout Impairs Leukemia Growth in PDX AML Models Revealing a New Therapeutic Vulnerability
Öz S; Heidelberg
J6. Understanding the influence of JAK3 germline vs. somatic variants
Vogt J; Munich
J7. Development and validation of an ELISA for the quantification of anti-ALK autoantibodies in ALCL Patients
Shephear W; Hamburg
J8. Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy
Teggatz M; Hamburg
12:30 – 14:00
12:30 – 14:00
Lunch (Wilsede, Heidemuseum)
Lunch (Wilsede, Heidemuseum)
14:00 – 14:30
14:00 – 15:30
(K) Invited Lecture
(K) Invited Letcure IV
Chair: Olaf Heidenreich
Matthias Peipp
Antibody-Engineering to improve Immunotherapy of Cancer
University Hospital Schleswig-Holstein, Kiel, Germany
14:30 – 15:30
(L) Translation & Therapy II
14:30 – 15:30
(L) Tumor microenviroment
Chair: Denis Schewe
L1. CRISPR-based optimization of CAR NK cell therapy for pediatric AML
Schuster S; Frankfurt am Main
L2. Glycosylation and Immune Evasion in Neuroblastoma
Schattling B; Hamburg
L3. miRNA signatures in Burkitt leukemia and lymphoma in children and young adults
Schneider B; Rostosck
L4. Mechanisms of cell death induced by NK cells in DLBCL
Vogler M; Frankfurt am Main
L5. Analysis of differential RNA expression suggests a key role of HDAC1 and let-7 in the pathogenesis of pineoblastoma
Müller M; Bonn
16:00 – 17:30
(M) Molecular Mechanisms of Disease II
15:30 – 16:00
15:30 – 16:00
Coffee break
Coffee break
16:00 – 17:30
(M) Molecular mechanisms of disease II
Chair: Mark Hartmann
M1. Characterization of childhood B-ALL cell lines to identify novel CIN-targeted therapies
Calvo C; Badalona
M2. Therapeutic targeting of the epigenetic network of NPM1c in acute myeloid leukemia
Javadpoor A; Frankfurt am Main
M3. Analyses of detailed reconstitution dynamics in Fanconi gene therapy
Remstedt K; Essen
M4. Investigating the Potential of BH3 Mimetics and NK Cell Immunotherapy in Pediatric Sarcoma Treatment
Pereira R S; Frankfurt am Main
M5. Deciphering the role of non-coding sequence variants predisposing to pediatric B-ALL
Wittibschalger S; Vienna
M6. Extrachromosomal DNA as a potential therapy target in a pediatric high-grade glioma mouse model with MYCN amplification
Mahnke B; Hamburg
M7. Targeting the HSP90-CDK9-Axis Sensitizes Pediatric AML (pAML) cells to Venetoclax
Vogt M; Düsseldorf
17:30 – 18:00
Coffee break
17:30 – 18:00
Coffee break
18:00 – 18:30
(N) Invited Lecture V
18:00 – 18:30
(N) Invited lecture
Chair: Dirk Heckl
Dr.med. Florian Perner
Deciphering epigentic mechanisms underlying disease persistence in AML
Hannover Medical School, Hannover, Germany
18:30 – 18:45
18:00 – 18:30
(N) Invited lecture
Wilsede Award
by Jan-Henning Klusmann
18:30 – 18:45
Wilsede award
19:00
Dinner
19:00
Dinner
SATURDAY, June 7, 2025
09:00 – 10:15
09:00 – 10:15
(O) Short talks I
(O) Translation & Therapy
Chair: Irmela Jeremias
O1. Spatial and temporal tumor heterogeneity representation in liquid biopsies of pediatric precision oncology patients
Zabel SF; Heidelberg
O2. Epigenetic maintenance of oncofetal identity in infant AML
Murmann N; Frankfurt am Main
O3. Clinical evaluation of ex vivo drug sensitivity profiling in the pediatric precision oncology program INFORM
Schmidt A; Heidelberg
O4. Targeting the fetal transcriptional landscape of pediatric AML
Groll D; Frankfurt am Main
O5. Development of a ROS- and lysosome-addressing combination treatment for relapsed Neuroblastoma
Smyrilli K; Heidelberg
O6. High-throughput drug screening of triple combinations in pediatric acute myeloid leukemia
Haas J; Frankfurt am Main
O7. Generation of iPSC-Derived Mesenchymal Stromal Cells (iMSCs) for Ex Vivo Acute Myeloid Leukemia (AML) Niche Models
Li Y; Utrecht
10:15 – 10:45
10:15 – 10:45
Coffee break
Coffee break
10:45 – 12:00
10:45 – 12:00
(P) Short talks II
(P) Molecular Mechanisms of Disease III
Chair: Christian Braun
P1. Identification of germline PAX5 variants in pediatric B-ALL: Establishing murine and hiPSC model systems for profiling
Haag R; Munich
P2. Exploring the translational potential of EZH2-controlled fetal gene signature in AML
Özcan E; Frankfurt am Main
P3. Digenic Heterozygous Variants in FANCF and FANCM Disrupt the Fanconi Anemia Pathway in Childhood Leukemia
Keller L; Munich
P4. Fine-mapping interactions of the N-terminal domain of GATA1 during leukemogenesis
Abdrbo A; Frankfurt am Main
P5. Understanding the role of linear ubiquitin in lysophagy and lysosomal cell death in diffuse large B-cell lymphoma
Celik G; Frankfurt am Main
P6. Investigating the role of GSK3β inhibition by Elraglusib in pediatric acute myeloid leukemia
Cifarelli L N; Frankfurt am Main
P7. CRISPR-Cas-Based Optimization of (CAR-)NK Cell Therapy in Pediatric AML
Kaffenberg C; Frankfurt am Main
12:00 – 13:00
12:00 – 13:00
Lunch
Lunch (Wilsede, Heidemuseum)
13:00
13:00
Departure
Departure
Many thanks for making this meeting possible:
Many thanks for making this meeting possible: